Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | -$0.73 | -$0.73 | -$0.73 |
Q2 2024 | 1 | -$0.79 | -$0.79 | -$0.79 |
Q3 2024 | 2 | -$3.53 | -$0.34 | -$1.24 |
Q1 2025 | 2 | -$3.58 | -$0.38 | -$1.28 |
Q2 2025 | 1 | -$1.34 | -$1.34 | -$1.34 |
Q3 2025 | 1 | -$0.91 | -$0.91 | -$0.91 |
Q4 2025 | 1 | -$0.92 | -$0.92 | -$0.92 |
Q1 2026 | 1 | -$0.94 | -$0.94 | -$0.94 |
Q2 2026 | 1 | -$0.86 | -$0.86 | -$0.86 |
Q3 2026 | 1 | -$0.81 | -$0.81 | -$0.81 |
Q4 2026 | 1 | -$0.79 | -$0.79 | -$0.79 |
Q1 2027 | 1 | -$0.77 | -$0.77 | -$0.77 |
Q2 2027 | 1 | -$0.76 | -$0.76 | -$0.76 |
Benitec Biopharma Inc. last posted its earnings results on Thursday, September 26th, 2024. The company reported $-1.32 earnings per share for the quarter, missing analysts' consensus estimates of $-0.49 by $0.83. The company had revenue of 0 for the quarter and had revenue of 216,000 for the year. Benitec Biopharma Inc. has generated $-5 earnings per share over the last year ($-5.36 diluted earnings per share) and currently has a price-to-earnings ratio of -5.91. Benitec Biopharma Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 11th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/14/2024 | Q1 2025 | -$0.48 | $0 | $0 | ||
09/26/2024 | Q4 2024 | -$0.49 | -$1.16 | -0.67 | $0 | $0 |
05/13/2024 | Q3 2024 | -$0.78 | -$1.64 | -0.86 | $6,000 | |
02/13/2024 | Q2 2024 | -$0.39 | -$2.64 | -2.25 | $0 | |
11/13/2023 | Q1 2024 | -$0.51 | -$2.76 | -2.25 | $0 | |
09/21/2023 | Q4 2023 | -$3.23 | -$2.83 | 0.4 | $7,000 | |
05/15/2023 | Q3 2023 | -$0.20 | -$2.71 | -2.51 | $54,000 | |
02/13/2023 | Q2 2023 | -$0.11 | -$3.22 | -3.11 | $14,000 | |
11/10/2022 | Q1 2023 | -$2.04 | -$8.78 | -6.74 | $14,681 | $472,000 |
09/02/2022 | Q4 2022 | -$4.76 | -$10.54 | -5.78 | $0 | |
05/16/2022 | Q3 2022 | -$7.48 | -$6.43 | 1.05 | $48,000 | |
02/14/2022 | Q2 2022 | -$10.03 | $25,000 | |||
11/15/2021 | Q1 2022 | -$10.50 | $0 | |||
09/20/2021 | Q4 2021 | -$9.64 | $6,664 | $2,000 | ||
05/12/2021 | Q3 2021 | -$14.00 | $1,000 | |||
02/09/2021 | Q2 2021 | -$0.75 | -$12.86 | -12.11 | $1,000 | |
11/13/2020 | Q1 2021 | -$0.92 | -$41.69 | -40.77 | $90,669 | $55,000 |
09/23/2020 | Q4 2020 | -$0.01 | -$45.40 | -45.39 | $183,584 | $-40,000 |
03/30/2020 | Q3 2020 | -$33.37 | $28,000 | |||
12/30/2019 | Q2 2020 | -$34.05 | $77,000 |
Benitec Biopharma Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 11th, 2025 based off last year's report dates.
The conference call for Benitec Biopharma Inc.'s latest earnings report can be listened to online.
The conference call transcript for Benitec Biopharma Inc.'s latest earnings report can be read online.
Benitec Biopharma Inc. (:BNTC) has a recorded annual revenue of $216,000.
Benitec Biopharma Inc. (:BNTC) has a recorded net income of $216,000. Benitec Biopharma Inc. has generated $-5.36 earnings per share over the last four quarters.
Benitec Biopharma Inc. (:BNTC) has a price-to-earnings ratio of -5.91 and price/earnings-to-growth ratio is -0.21.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED